Trial Profile
A study evaluating clinical experience of patients treated with Nintedanib for Idiopathic pulmonary fibrosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2017 New trial record